ESTRO 36 Abstract Book

Proffered Papers Dosimetry and detector development . ...........................................................................Abs. 530-535 Novel methods for auditing ..........................................................................................Abs. 536-541 Patient safety and treatment outcome ...........................................................................Abs. 542-547 Poster Viewing Session 12: Gynaecology and prostate . .........................................................................Abs. 548-554

TUESDAY 9 MAY 2017 Teaching lecture

New radiotherapeutic horizons in soft tissue sarcoma treatment .............................................. Abs. 555 Clinical evidence for hypofractionation in prostate cancer what is the optimum? ......................... Abs. 556 Extracellular vesicles in radiation oncology ........................................................................... Abs. 557 Update on molecular radiotherapy ....................................................................................... Abs. 558 Basics, implementations, limitations, … of Monte Carlo dose calculation algorithms .................... Abs. 559 RTTs roles and responsibilities to support future practice ........................................................ Abs. 560 Symposium Radiotherapy in the elderly ..........................................................................................Abs. 561-564 Symposium with Proffered Papers Selection of patients and radiotherapy technique for APBI in the light of new phase III trial data . ..........................................................................................Abs. 565-569 Novel approaches in poor tumour control sites ................................................................Abs. 570-573 Symposium 4D imaging and tracked delivery ...................................................................................Abs. 574-576 Modelling and treatment customisation ..........................................................................Abs. 577-579 RT is technology driven. How to keep the patient involved? . .............................................Abs. 580-582 Hypofractionation in prostate cancer . ............................................................................Abs. 583-585 Is there any ground for boost brachytherapy in the time of high precision IGRT/IMRT? .........Abs. 586-588 Symposium with Proffered Papers Novel approaches in tumour control ..............................................................................Abs. 589-591 Symposium Applications and challenges in dosimetry for MR-linacs .....................................................Abs. 592-594 Novel approaches for combining imaging and non-imaging data for radiotherapy response predicition .............................................................................Abs. 595-597 Debate Debate: Precision in radiotherapy: mission complete! . ........................................................... Abs. 598 POSTERS Clinical track: Head and Neck .......................................................................................Abs. 603-621 Clinical track: CNS ......................................................................................................Abs. 622-644 Clinical track: Haematology ..........................................................................................Abs. 645-648 Clinical track: Breast ...................................................................................................Abs. 649-665 Clinical track: Lung .....................................................................................................Abs. 666-678 Clinical track: Upper GI (oesophagus, stomach, pancreas, liver) ........................................Abs. 679-701 Clinical track: Lower GI (colon, rectum, anus) . ...............................................................Abs. 702-707 Clinical track: Gynaecological (endometrium, cervix, vagina, vulva) ...................................Abs. 708-722 Clinical track: Prostate ................................................................................................Abs. 723-739 Clinical track: Skin cancer / malignant melanoma ............................................................Abs. 740-741 Clinical track: Sarcoma ................................................................................................Abs. 742-744 Clinical track: Palliation ...............................................................................................Abs. 745-747 Clinical track: Elderly ..................................................................................................Abs. 748-749 Clinical track: Health services research / health economics ...............................................Abs. 750-751 Clinical track: Other ....................................................................................................Abs. 752-755 Physics track: Basic dosimetry and phantom and detector development ..............................Abs. 756-784 Physics track: Dose measurement and dose calculation ....................................................Abs. 785-812 Physics track: Radiation protection, secondary tumour induction and low dose (incl. imaging) . .......................................................................................Abs. 813-815 Physics track: Treatment plan optimisation: algorithms ....................................................Abs. 816-823 Physics track: Treatment planning: applications ..............................................................Abs. 824-845 Physics track: (Radio)biological modelling ......................................................................Abs. 846-855 Physics track: Intra-fraction motion management ............................................................Abs. 856-865 Physics track: Inter-fraction motion management (excl. adaptive radiotherapy) ...................Abs. 866-874 Physics track: Adaptive radiotherapy for inter-fraction motion management ........................Abs. 875-880